Study: Mesothelioma Survival Rates Rise with SMART Protocol
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a larger clinical trial at the Princess Margaret Cancer Centre in Toronto. Lancet Oncology recently published results of the study, named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. The SMART study involved 96 patients with pleural mesothelioma who were treated in Toronto from 2008 to 2019. All received the intensity-modulated radiotherapy before extrapleural pneumonectomy surgery, an unconventional treatment regimen. Among the...
Source: Asbestos and Mesothelioma News - January 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Thoracic Chemotherapy May Advance Mesothelioma Treatment
Thoracic surgeon Dr. Marcello Migliore is convinced that adding hyperthermic intrathoracic chemotherapy to aggressive surgery can extend survival significantly for patients with pleural mesothelioma cancer. He wants others to know that, too. This seldom-used, controversial procedure, also known as HITHOC, involves circulating a heated, high-concentration chemotherapy solution throughout the chest cavity for 60 minutes immediately following aggressive mesothelioma surgery. The idea is to kill any microscopic tumor cells that evaded the surgeon, hopefully slowing a potential cancer recurrence. Unlike HIPEC, a similar procedu...
Source: Asbestos and Mesothelioma News - January 19, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Statins May Give Boost to Mesothelioma Immunotherapy Drugs
This study, which included both patients with pleural mesothelioma and with advanced non-small cell lung cancer, found a potential synergy with the immunotherapy drugs. Opdivo and Keytruda, generically called nivolumab and pembrolizumab, respectively, are known as PD-1 inhibitors, drugs that restrict a protein from stopping immune response to cancer cells. “Statins may lead to prolonged antigen retention on cell membrane and strengthen antigen presentation to T cells, thus suggesting a potential synergy with PD-1 inhibitors,” the authors wrote. “The anti-tumor effect of statins might be attributed to an i...
Source: Asbestos and Mesothelioma News - January 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

EPA Evaluation Finds Asbestos Still An Unreasonable Risk
The U.S. Environmental Protection Agency released Part 1 of its Final Risk Evaluation for Asbestos, reaffirming preliminary findings from March that were roundly criticized for underestimating the dangers of exposure to this toxic mineral. Six ongoing use categories of asbestos were evaluated by the EPA, which found 16 conditions of use that presented unreasonable risk to human health through either occupational exposures or consumer uses. Part 1 of the evaluation, released in late December 2020, involved the chrysotile type of asbestos. Chrysotile is the only type of asbestos being imported, processed or distributed for u...
Source: Asbestos and Mesothelioma News - January 6, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

What Is the Main Cause of Mesothelioma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - December 30, 2020 Category: General Medicine Source Type: news

Regulatory loophole blamed for asbestos detected in bath mats: Series of bath mats and other items containing asbestos discovered among...
TOKYO -- A series of bath mats and other items containing asbestos have been discovered since November among (Source: Reuters: Health)
Source: Reuters: Health - December 27, 2020 Category: Consumer Health News Source Type: news

Judge Rules EPA Must Tighten Asbestos Data Collection
United States District Judge Edward Chen has ordered the Environmental Protection Agency to improve its data collection on the amount of asbestos and asbestos products that are coming into the country. Chen issued his ruling Tuesday in San Francisco, stemming from a lawsuit brought against the EPA by a group of nonprofit organizations wanting to close the current asbestos reporting loopholes. The EPA has contended that the voluntary reporting today by manufacturers, processors and importers provided adequate data. “EPA has not articulated a satisfactory explanation for its decision not to use its significant enforcem...
Source: Asbestos and Mesothelioma News - December 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Top 10 Mesothelioma and Asbestos News Stories of 2020
Growing allegations of asbestos-contaminated talc in various consumer products, coupled with historic approval of a new treatment for pleural mesothelioma, made 2020 a year filled with both anxiety and hope. Johnson & Johnson stopped selling its iconic baby powder in May after being hit by thousands of lawsuits contending its talc-based product was causing various cancers, including ovarian cancer and malignant mesothelioma. The U.S. Food and Drug Administration approved the immunotherapy combination of Opdivo and Yervoy in October, the first new drug regimen approved for first-line treatment of unresectable disease in...
Source: Asbestos and Mesothelioma News - December 15, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

South Africa: Families Abandoned to Deadly Asbestos Risk
[GroundUp] Several hundred people, including children, are living in an abandoned old age home with crumbling asbestos roofs in Makhanda. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 10, 2020 Category: African Health Source Type: news

Differentiation of the Cs in lung cancer: Cancer vs. COVID, British Thoracic Society
Urgent referrals for cancer in general and for lung cancer specifically have fallen during the COVID-19 pandemic that will likely lead to an increase in mortality and morbidity from lung cancer. The appendix reproduces a submission by the Clinical Expert Group for lung cancer and mesothelioma which includes recommendations about differentiation of symptoms from lung cancer from those due to COVID-19 and recommendations for easy access of patients with concerning symptoms for assessment by primary care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 3, 2020 Category: Consumer Health News Source Type: news

Study: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing clinical trial. Median overall survival was more than four months better than the control group receiving chemotherapy alone in the randomized trial. ONCOS-102 is manufactured by Targovax, a small Scandinavian biotech company focused on...
Source: Asbestos and Mesothelioma News - December 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Some Talc Products Contain Asbestos: Study
Title: Some Talc Products Contain Asbestos: StudyCategory: Health NewsCreated: 11/30/2020 12:00:00 AMLast Editorial Review: 12/1/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 1, 2020 Category: Cancer & Oncology Source Type: news

Some Talc Products Contain Asbestos: Study
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 30, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Cosmetic Surgery, Preventive Medicine, News, Source Type: news

Some Talc Products Contain Asbestos: Study
MONDAY, Nov. 30, 2020– Nearly 15% of talc-based cosmetic products analyzed in a recent study contained asbestos. Environmental Working Group (EWG) -- an American advocacy nonprofit that commissioned the tests and did the analysis -- said... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 30, 2020 Category: General Medicine Source Type: news

Mesothelioma Patient Research Expanding in United Kingdom
The University of Sheffield has launched the Mesothelioma UK Research Centre-Sheffield, the country’s first experience-based program designed to improve the treatment and care of patients diagnosed with this aggressive, asbestos-related cancer. Based in South Yorkshire, England, the University of Sheffield hopes to become an international pioneer in patient-led mesothelioma research. “The program will build on our legacy of research from a number of years,’’ Dr. Clare Gardiner, of the University of Sheffield Health Sciences School and program co-director, told The Mesothelioma Center at Asbestos.co...
Source: Asbestos and Mesothelioma News - November 30, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

CT shows damaging effects of wood smoke on lungs
CT shows damage caused to the lungs in people who cook with natural fuels such...Read more on AuntMinnie.comRelated Reading: CT shows COVID-19 causes lingering lung damage COVID-19 patients face higher risk of barotrauma CT shows parallels between vaping lung injury, COVID-19 Canadian CT lung screening tracks asbestos workers CT distinguishes asbestos lung damage from smoking impairment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 25, 2020 Category: Radiology Source Type: news

Mesothelioma Surgery with Organ Removal Extends Survival
Removing major organs to achieve a more complete cancer resection did not increase severe complications or hinder survival benefits of aggressive surgery for patients with peritoneal mesothelioma, according to a recent report. The increased complexity of organ resection surgery will not adversely affect long-term outcomes, according to the multicenter study published in Annals of Surgical Oncology. By comparison, an incomplete cytoreduction that can spare the organs is associated with increased mortality and shorter overall survival. The study, which involved 174 patients across 12 specialty centers within the U.S., accent...
Source: Asbestos and Mesothelioma News - November 17, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

South Africa: ANC's Ace Magashule Appears in Court
[Daily Maverick] Nthabiseng Ligelebane has lived in her family home in Dihlabeng, Free State, for 58 years but only recently became aware that the house's asbestos roof was a hazard to her health. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 13, 2020 Category: African Health Source Type: news

MRI May Best CT for Assessing Mesothelioma Tumor Volume MRI May Best CT for Assessing Mesothelioma Tumor Volume
MRI offers advantages over CT for assessing primary-tumor volume in patients with mesothelioma, researchers from UK report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 9, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Johnson & Johnson Fails to Overturn $2.12 Billion Baby Powder Verdict, Plans Supreme Court Appeal Johnson & Johnson Fails to Overturn $2.12 Billion Baby Powder Verdict, Plans Supreme Court Appeal
Missouri's highest court on Tuesday refused to consider Johnson& Johnson's appeal of a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in its baby powder and other talc products.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 5, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trial targets deadly lung cancer
(Flinders University) With more than 650 Australians diagnosed with malignant mesothelioma last year, Flinders University is leading new research to discover alternatives to chemotherapy and even prevent deaths by early detection in future. One novel approach, using natural therapeutic benefits of curcumin, a key component of the spice turmeric, will be put to the test in a clinical trial in 2021 as part of world-leading research at Flinders University. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 30, 2020 Category: Cancer & Oncology Source Type: news

Tiny golden bullets could help tackle asbestos-related cancers
(University of Cambridge) Gold nanotubes - tiny hollow cylinders one thousandth the width of a human hair - could be used to treat mesothelioma, a type of cancer caused by exposure to asbestos, according to a team of researchers at the Universities of Cambridge and Leeds. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2020 Category: Cancer & Oncology Source Type: news

Rural U.S. Hospitals Are On Life Support As a Third Wave of COVID-19 Strikes
When COVID-19 hit the Southwest Georgia Regional Medical Center in Cuthbert, a small rural town in Randolph County, in late March, the facility—which includes a 25-bed hospital, an adjacent nursing home and a family-medicine clinic, was quickly overwhelmed. In just a matter of days, 45 of the 62 nursing home residents tested positive. Negative residents were isolated in the hospital while the severely ill patients from both the nursing home and the local community were transferred to other better-equipped facilities. “We were trying to get the patients out as fast as possible,” says Steve Whatley, Southwe...
Source: TIME: Health - October 20, 2020 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 Source Type: news

Latest T-Cell Clinical Trial Opens for Mesothelioma Patients
Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most promising — clinical trial involving T-cell therapy. The novel study stems from the U.S. Food and Drug Administration’s recent Investigational Drug Application approval of ATA2271, a chimeric antigen receptor known as CAR T-cell therapy. This latest therapy will be tested in a phase I, dose-escalation clinical trial. It will involve the removal and genetic modification of a patient’s T cells, a type of white blood cell, that will be separated in the la...
Source: Asbestos and Mesothelioma News - October 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Congress Fails to Vote on Asbestos Ban Legislation
The U.S. House of Representatives last week failed to advance once-promising legislation that effectively would have banned asbestos, frustrating advocates once again. H.R. 1603, titled the Alan Reinstein Ban Asbestos Now Act of 2020, had been expected to pass easily under a Congressional procedure reserved for broadly supported, non-controversial legislation. The bipartisan House Committee on Energy and Commerce had voted earlier, 47-1, to move it forward, fueling considerable optimism leading into the latest Congressional session. If passed, the bill would have then moved to the U.S. Senate, which also had shown bipartis...
Source: Asbestos and Mesothelioma News - October 7, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Johnson & Johnson Settles 1K Baby Powder-Asbestos Lawsuits
Pharmaceutical giant Johnson & Johnson has agreed to pay more than $100 million to settle an more than a thousand lawsuits claiming its iconic baby powder caused cancer, according to Bloomberg News. The settlement stems from burgeoning litigation after earlier asbestos-contaminated talc was found in one of its products. Johnson & Johnson, the world’s largest maker of health care merchandise, recalled 33,000 bottles of its baby powder in 2019, “out of an abundance of caution.” It also stopped selling talc-based baby powder the same year in the United States and Canada, switching to a cornstarch-ba...
Source: Asbestos and Mesothelioma News - October 6, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Johnson & Johnson Will Pay $100M in Baby Powder Lawsuits
Pharmaceutical giant Johnson & Johnson has agreed to pay more than $100 million to settle more than a thousand lawsuits claiming its iconic talc-based baby powder caused cancer, according to Bloomberg News. The settlement stems from burgeoning litigation after earlier asbestos-contaminated talc was found in one of its products. Johnson & Johnson, the world’s largest maker of health care merchandise, recalled 33,000 bottles of its baby powder in 2019, “out of an abundance of caution.” It also stopped selling talc-based baby powder the same year in the United States and Canada, switching to a corns...
Source: Asbestos and Mesothelioma News - October 6, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Drug Combo Approved for First-Line Treatment of Mesothelioma
Title: Drug Combo Approved for First-Line Treatment of MesotheliomaCategory: Health NewsCreated: 10/5/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 6, 2020 Category: Cancer & Oncology Source Type: news

Drug Combo Approved for First - Line Treatment of Mesothelioma
Opdivo - Yervoy combination approved to treat adults with unresectable malignant pleural mesothelioma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 6, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Drug Combo Approved for First-Line Treatment of Mesothelioma
MONDAY, Oct. 5, 2020 -- On Friday, the U.S. Food and Drug Administration announced the approval of a drug combination for first-line treatment of unresectable malignant pleural mesothelioma (MPM) -- the first drug regimen to be approved for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 5, 2020 Category: General Medicine Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA OKs Combo Therapy for First-Line Mesothelioma Treatment FDA OKs Combo Therapy for First-Line Mesothelioma Treatment
Combination nivolumab and ipilimumab has now been approved as first-line treatment in mesothelioma and possibly a new standard of care.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
PRINCETON, N.J.--(BUSINESS WIRE) October 2, 2020 -- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 2, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

KCIC Report: Mesothelioma Lawsuits on the Rise in US
While the incidence of malignant mesothelioma in the United States continued its gradual decline, the tendency to sue for damages drastically increased in recent years, according to a KCIC study. Lawsuits filed by those stricken with the deadly asbestos-related cancer increased 65.7% from 2007 to 2017. Meanwhile, the overall incidence rate of mesothelioma dropped 16.2% during the same period. KCIC, a well-regarded consulting firm in Washington, D.C., that manages asbestos product liabilities, published the study of mesothelioma and asbestos litigation last week. Study author Megan Shockley, senior manager at KCIC, was unav...
Source: Asbestos and Mesothelioma News - September 29, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Gene Therapy Clinical Trial for Mesothelioma Moving Forward
This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group. Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll. Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - September 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Peer Review Finds EPA ’s Asbestos Risk Evaluation Flawed
The Science Advisory Committee on Chemicals found considerable failings and an underestimation of danger to the general public in a draft risk evaluation of asbestos submitted earlier this year by the U.S. Environmental Protection Agency. SACC, which serves as a scientific, peer-review mechanism for the EPA, released its recommendations last week in the ongoing governmental reevaluation of asbestos. This is the latest step in the amended Toxic Substances Control Act that requires the EPA to conduct evaluations on specific chemicals to determine whether they present unreasonable risk under conditions of use. The committee w...
Source: Asbestos and Mesothelioma News - September 2, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Georgia-Pacific Pledges $1B to Bestwall Asbestos Trust Fund
Georgia-Pacific has pledged $1 billion to fund an asbestos trust for bankrupt affiliate Bestwall LLC, clearing the path to a settlement of longstanding liability claims involving mesothelioma cancer. Bloomberg Law reported earlier this month that Georgia-Pacific made the financial commitment to advance a consensual resolution in the U.S. Bankruptcy Court for the Western District of North Carolina. Bestwall is a wallboard and joint compound product manufacturer that filed for Chapter 11 bankruptcy in 2017 with more than 62,000 pending claims involving asbestos. It was known earlier as Bestwall Gypsum Company, and was purcha...
Source: Asbestos and Mesothelioma News - August 25, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Lung Cancer Trial Could Benefit Mesothelioma Patients
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II clinical research trial is focusing on non-small cell lung cancer and will enroll approximately 66 patients across the U.S. Keytruda, Merck’s anti-PD-1 therapy, works as a checkpoint inhibitor and allows the immune system to identify and attack cancer cells hiding within the PD-1 pathway. The FDA approved Keytruda for mesothelioma as the first immunotherapy treatment for the disease in 2020. Novocure, a global oncology company, has been developing...
Source: Asbestos and Mesothelioma News - August 19, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Immunotherapy Combination Extends Mesothelioma Survival
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination. Patients in the randomized mesothelioma clinical trial who were treated with ipilimumab (Yervoy) and nivolumab (Opdivo) had a median overall survival of 18.1 months, compared to 14.1 months for those receiving chemotherapy. The results of the mesothelioma trial, which was sponsored by Bristol Myers Squibb, were presented at the recent World Conference on Lung Cancer virtual meeting. Authors of the study said it was the first time an immuno...
Source: Asbestos and Mesothelioma News - August 11, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Chemo-Free Management of Mesothelioma on Horizon Chemo-Free Management of Mesothelioma on Horizon
Combination immunotherapy with nivolumab and ipilimumab could replace chemotherapy for patients with treatment-naive mesothelioma, suggest new phase 3 trial data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mesothelioma Clinical Trials Resume After COVID-19 Disruption
When the COVID-19 pandemic struck earlier this year, clinical trials at medical centers around the world slowed enrollment or placed trial activities on hold. As businesses begin to reopen in the United States, more treatment centers are resuming mesothelioma study activities and ramping up enrollment. Clinical research trials offer patients access to experimental mesothelioma treatments that haven’t yet been approved by the U.S. Food and Drug Administration. These treatments may provide higher chances of survival than the current standard of care. “So far, every patient I have seen during the COVID-19 pande...
Source: Asbestos and Mesothelioma News - August 10, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - August 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

MD Anderson Leads List of Top-Tier Cancer Hospitals
For the sixth consecutive year, University of Texas MD Anderson Cancer Center in Houston was named the top Adult Cancer Hospital in America by U.S. News & World Report. Several of the top-tier cancer centers on the list have specialty programs for mesothelioma that contributed to their high ranking. The 2020-21 Best Hospitals for Cancer rankings, announced this week, are part of a broader Best Hospitals Honor Roll done annually by U.S. News & World Report. Top five cancer center rankings also included Memorial Sloan Kettering in New York City; Mayo Clinic in Rochester, Minnesota; Johns Hopkins Hospital in Baltimore...
Source: Asbestos and Mesothelioma News - July 29, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Specialty Centers Rank on 2020 Best Hospitals List
For the sixth consecutive year, University of Texas MD Anderson Cancer Center in Houston was named the top Adult Cancer Hospital in America by U.S. News & World Report. Several of the top-tier cancer centers on the list have specialty programs for mesothelioma that contributed to their high ranking. The 2020-21 Best Hospitals for Cancer rankings, announced this week, are part of a broader Best Hospitals Honor Roll done annually by U.S. News & World Report. Top five cancer center rankings also included Memorial Sloan Kettering in New York City; Mayo Clinic in Rochester, Minnesota; Johns Hopkins Hospital in Baltimore...
Source: Asbestos and Mesothelioma News - July 29, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study Shows Peritoneal Mesothelioma Surgery Underutilized
The continued underutilization of aggressive surgery for peritoneal mesothelioma is shortening survival time dramatically for patients who could qualify for, and benefit from, the highly effective procedure. Only a third of those diagnosed with peritoneal mesothelioma are undergoing potentially curative cytoreductive mesothelioma surgery, according to a comprehensive study of the National Cancer Database by researchers at Inova Fairfax Medical Center in Virginia. Annals of Surgical Oncology published the mesothelioma study earlier this year. “Patients who have the surgery perform much better than those who do not. Ye...
Source: Asbestos and Mesothelioma News - July 28, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news